Primary hyperparathyroidism: an update (Q37796577)

23 August 2017

title

Primary hyperparathyroidism: an update (English)

1 reference

primary hyperparathyroidism

23 August 2017

1 reference

1 reference

Zeina Habib

1 reference

23 August 2017

Pauline Camacho

series ordinal

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20890202

25 July 2024

publication date

1 December 2010

1 reference

full work available at URL

23 August 2017

https://journals.lww.com/01266029-201012000-00011

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Current Opinion in Endocrinology, Diabetes and Obesity

25 July 2024

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

554-560

1 reference

The diagnosis and management of asymptomatic primary hyperparathyroidism revisited

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

“Incipient” Primary Hyperparathyroidism: A “Forme Fruste” of an Old Disease

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Role of Growth Factors on Human Parathyroid Adenoma Cell Proliferation

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

The role of menin in parathyroid tumorigenesis.

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Calcium-sensing receptor autoantibodies in primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Hyperparathyroidism and malnutrition with severe vitamin D deficiency

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Primary hyperparathyroidism from parathyroid microadenoma: specific features and implications for a surgical strategy in the era of minimally invasive parathyroidectomy

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

The impact of baseline intact parathyroid hormone levels on severity of primary hyperparathyroidism and outcomes in patients undergoing surgery

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Assessing the impact of low baseline parathyroid hormone levels on surgical treatment of primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Neurocognitive dysfunction: a predictor of parathyroid hyperplasia

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Sporadic primary hyperparathyroidism in young individuals: different disease and treatment?

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Evaluation of subclinical coronary atherosclerosis in mild asymptomatic primary hyperparathyroidism patients

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Carotid vascular abnormalities in primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Endothelial function and endothelial nitric oxide synthase intron 4a/b polymorphism in primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism.

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Prevalence of type 2 diabetes mellitus in patients with primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism.

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Cardiovascular risk factors in primary hyperparathyroidism.

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy.

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Neuropsychological features in primary hyperparathyroidism: a prospective study

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

High prevalence of simple kidney cysts in patients with primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Calcium-sensing receptor (CASR) mutations in hypercalcemic states: studies from a single endocrine clinic over three years

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

MEN1 gene analysis in patients with primary hyperparathyroidism: 10-year experience of a single institution for thyroid and parathyroid care in Japan

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Impact of 25 hydroxyvitamin D deficiency in perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Role of vitamin D deficiency in continued hyperparathyroidism following parathyroidectomy

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency.

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D.

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Alendronate therapy in men with primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

The efficacy and safety of intravenous bisphosphonates in the treatment of primary hyperparathyroidism complicated by hypercalcemia crisis

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Parathyroidectomy in the elderly population: does age really matter?

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Outpatient minimally invasive parathyroidectomy is safe for elderly patients.

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Postoperative mortality in parathyroid surgery in Sweden during five decades: improved outcome despite older patients

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Potential utility of high preoperative levels of serum type I collagen markers in postmenopausal women with primary hyperparathyroidism with respect to their short-term variations after parathyroidectomy

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Effect of bone mineral density and parathyroidectomy on fracture risk in primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Patients with primary hyperparathyroidism--why do some form stones?

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Clinical and laboratory characteristics of calcium stone-formers with and without primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Parathyroidectomy improves functional capacity in "asymptomatic" older patients with primary hyperparathyroidism: a randomized control trial

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

The long-term benefit of parathyroidectomy in primary hyperparathyroidism: a 10-year prospective surgical outcome study

25 July 2024

1 reference

https://api.crossref.org/works/10.1097/MED.0B013E32833F47E4

25 July 2024

Identifiers

DOI

1 reference

23 August 2017

1 reference